Mitochondria toxicity of antihyperlipidemic agents bezafibrate and fenofibrate

Diabetology International

Volumn 4, Issue 2, 2013, Pages 126-131

  Yamada, K ^a   Tsunoda, K ^b   Kawai, K ^c   Ikeda, T ^a   Taguchi, K ^a   Kajita, K ^c   Morita, H ^c   Ishizuka, T ^c  

^a Gifu Municipal Hospital   (Japan)

^b Kagoshima Immaculate Heart University   (Japan)

^c GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antihyperlipidemic agents; Bezafibrate; Fenofibrate; Mitochondria toxicity

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BEZAFIBRATE; FENOFIBRATE; HYDROLASE; PHENYLENEDIAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ANIMAL CELL; ARTICLE; CYTOTOXICITY; DRUG CYTOTOXICITY; ELECTRON TRANSPORT; ENERGY TRANSFER; ENZYME ACTIVITY; LIVER MITOCHONDRION; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN; SUBMITOCHONDRIAL PARTICLE;

EID: 84880405719     PISSN: 21901678     EISSN: 21901686     Source Type: Journal    
DOI: 10.1007/s13340-012-0104-9     Document Type: Article

References (15)

1. Rajamani K, Colman PG, Li L-P, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC, on behalf of the FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomized controlled trial. Lancet. 2009;373: 1780-8.
2. The BIP study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) Study. Circulation. 2000;102: 21-7.
3. Balfour JA, McTavish D, IIeel RC. Fenofibrate. A review of its pharmacodynamics and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs. 1990;40: 260-90.
4. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, Baba S. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care. 1988;11: 495-9.
5. Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophs Res Commun. 2002;296: 293-9.
6. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic disease and peroxisome proliferator-activated receptors. Endocrinology. 2003;144: 2201-7.
7. Zou S, Wallace KB. The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol Sci. 1999;48: 82-9.
8. Brunmair B, Lest A, Staniek K, Gras F, Scharf N, Roden M, Nohl H, Werner Waldhausl W, Furnsinn C. Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp. 2004;311: 109-14.
9. Erecinska M, Wilson DF. Inhibitors of mitochondrial function. Oxford: Pergamon Press; 1981.
10. Schuneider WC. Intracellular distribution of enzymes III. The oxidation of octanoic acid by rat liver fractions. J Biol Chem. 1948;176: 259-66.
11. Ruzicka HJ, Crane F. Quinone interaction with the respiratory chain-linked NADH dehydrogenase of beef heart mitochondria. I. Juglone reductase activity. Biochim Biophys Acta. 1970;223: 71-85.
12. Chance B, Williams GR. Respiratory enzymes and oxidative phosphorylation. J Biol Chem. 1955;219: 383-438.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;143: 265-75.
14. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109: 2197-202.
15. Tenebaum A, Fisman EZ, Boyko V, Benderly M, Tanne d, Haim M, Matas Z, Motro M, Behar S. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006;166: 737-41.